Keros Therapeutics is a biotechnology company dedicated to the discovery and development of therapeutics for hematological and musculoskeletal disorders. Its lead protein therapeutic product candidate, KER-050, is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. Keros Therapeutics' small molecule product candidate, KER-047, is designed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva. The company also develops KER-01, a preclinical protein therapeutic product candidate that is designed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.